Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2009 1
2010 1
2011 1
2012 1
2015 2
2017 1
2018 2
2019 3
2020 5
2021 3
2023 1
2024 1
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

16 results

Results by year

Filters applied: . Clear all
Page 1
Clinical Benefits of Preconditioning Intervention in Patients with Relapsed or Refractory Acute Myelogenous Leukemia Who Underwent Allogeneic Hematopoietic Cell Transplantation: A Kanto Study of Group for Cell Therapy Multicenter Analysis.
Tachibana T, Kanda J, Ishizaki T, Najima Y, Tanaka M, Doki N, Fujiwara SI, Kimura SI, Onizuka M, Takahashi S, Saito T, Mori T, Fujisawa S, Sakaida E, Miyazaki T, Aotsuka N, Gotoh M, Watanabe R, Shono K, Usuki K, Tsukada N, Kanamori H, Kanda Y, Okamoto S; Kanto Study Group for Cell Therapy (KSGCT). Tachibana T, et al. Transplant Cell Ther. 2021 Jan;27(1):70.e1-70.e8. doi: 10.1016/j.bbmt.2020.09.025. Epub 2020 Sep 30. Transplant Cell Ther. 2021. PMID: 33007494 Free article.
Allogeneic hematopoietic stem cell transplantation for aplastic anemia with pre-transplant conditioning using fludarabine, reduced-dose cyclophosphamide, and low-dose thymoglobulin: A KSGCT prospective study.
Kako S, Kanda Y, Onizuka M, Aotsuka N, Usuki K, Tachibana T, Kobayashi T, Kato J, Yano S, Shimizu H, Shono K, Tanaka M, Tsukamoto S, Mori T, Yamazaki E, Najima Y, Hangaishi A, Hoshino T, Watanabe R, Matsumoto K, Okamoto S; for Kanto Study Group for Cell Therapy (KSGCT). Kako S, et al. Am J Hematol. 2020 Mar;95(3):251-257. doi: 10.1002/ajh.25693. Epub 2019 Dec 19. Am J Hematol. 2020. PMID: 31804748 Free article. Clinical Trial.
Outcomes and Prognostic Factors for Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia Who Underwent Allogeneic Hematopoietic Cell Transplantation: A KSGCT Multicenter Analysis.
Tachibana T, Kanda J, Ishizaki T, Najima Y, Tanaka M, Doki N, Fujiwara SI, Kimura SI, Onizuka M, Takahashi S, Saito T, Mori T, Fujisawa S, Sakaida E, Matsumoto K, Aotsuka N, Gotoh M, Watanabe R, Shono K, Usuki K, Tsukada N, Kanamori H, Kanda Y, Okamoto S; Kanto Study Group for Cell Therapy (KSGCT). Tachibana T, et al. Biol Blood Marrow Transplant. 2020 May;26(5):998-1004. doi: 10.1016/j.bbmt.2020.01.007. Epub 2020 Jan 18. Biol Blood Marrow Transplant. 2020. PMID: 31962165 Free article.
[Second transplantation for graft failure after allogeneic hematopoietic stem cell transplantation--a retrospective survey by Kanto Study Group for Cell Therapy].
Hagihara M, Kanamori H, Sakai M, Mori T, Nakaseko C, Aotsuka N, Uehara T, Sakura T, Yoshiba F, Kawai N, Tanaka M, Fujisawa S, Ohwada C, Wakita H, Yokota A, Kawamura T, Maruta A, Sakamaki H, Okamoto S; Kanto Study Group for Cell Therapy (KSGCT). Hagihara M, et al. Rinsho Ketsueki. 2010 Jun;51(6):390-7. Rinsho Ketsueki. 2010. PMID: 20622484 Japanese.
Pre-conditioning intervention in patients with relapsed or refractory acute lymphoblastic leukemia who underwent allogeneic hematopoietic cell transplantation: a KSGCT multicenter retrospective analysis.
Tachibana T, Kanda J, Ishizaki T, Najima Y, Tanaka M, Doki N, Fujiwara SI, Kimura SI, Onizuka M, Takahashi S, Saito T, Mori T, Fujisawa S, Sakaida E, Miyazaki T, Aotsuka N, Gotoh M, Watanabe R, Shono K, Kanamori H, Kanda Y, Okamoto S; Kanto Study Group for Cell Therapy (KSGCT). Tachibana T, et al. Ann Hematol. 2021 Nov;100(11):2763-2771. doi: 10.1007/s00277-021-04607-8. Epub 2021 Aug 6. Ann Hematol. 2021. PMID: 34357435
Allogeneic hematopoietic cell transplantation in patients with untreated acute myeloid leukemia: a KSGCT multicenter retrospective analysis.
Tachibana T, Ishizaki T, Takahashi S, Najima Y, Kimura SI, Sakaida E, Onizuka M, Mori T, Fujisawa S, Fujiwara SI, Saito T, Hagihara M, Aotsuka N, Gotoh M, Usuki K, Tsukada N, Kanda J, Kanamori H, Kanda Y, Okamoto S; Kanto Study Group for Cell Therapy (KSGCT). Tachibana T, et al. Bone Marrow Transplant. 2020 Jul;55(7):1497-1501. doi: 10.1038/s41409-019-0689-8. Epub 2019 Sep 19. Bone Marrow Transplant. 2020. PMID: 31537900 No abstract available.
Deferasirox for the treatment of iron overload after allogeneic hematopoietic cell transplantation: multicenter phase I study (KSGCT1302).
Tachibana T, Kanda J, Machida S, Saito T, Tanaka M, Najima Y, Koyama S, Miyazaki T, Yamamoto E, Takeuchi M, Morita S, Kanda Y, Kanamori H, Okamoto S; Kanto Study Group for Cell Therapy (KSGCT). Tachibana T, et al. Int J Hematol. 2018 May;107(5):578-585. doi: 10.1007/s12185-017-2396-9. Epub 2018 Jan 5. Int J Hematol. 2018. PMID: 29305770 Clinical Trial.
Clinical significance of late CMV disease in adult patients who underwent allogeneic stem cell transplant.
Shimizu H, Najima Y, Kako S, Tanaka M, Fujiwara SI, Mori T, Usuki K, Gotoh M, Hagihara M, Tsukada N, Oniduka M, Takada S, Sakaida E, Fujisawa S, Onoda M, Aotsuka N, Yano S, Ohashi K, Takahashi S, Okamoto S, Kanda Y; Kanto Study Group for Cell Therapy (KSGCT). Shimizu H, et al. J Infect Chemother. 2023 Dec;29(12):1103-1108. doi: 10.1016/j.jiac.2023.07.015. Epub 2023 Aug 1. J Infect Chemother. 2023. PMID: 37532223
Pharmacokinetics of intravenous busulfan as condition for hematopoietic stem cell transplantation: comparison between combinations with cyclophosphamide and fludarabine.
Kikuchi T, Mori T, Ohwada C, Onoda M, Shimizu H, Yokoyama H, Onizuka M, Koda Y, Kato J, Takeda Y, Hino Y, Mishina T, Sakaida E, Shono K, Nagao Y, Yokota A, Matsumoto K, Morita K, Okamoto S; Kanto Study Group for Cell Therapy (KSGCT). Kikuchi T, et al. Int J Hematol. 2021 Jan;113(1):128-133. doi: 10.1007/s12185-020-02990-y. Epub 2020 Sep 4. Int J Hematol. 2021. PMID: 32886279
16 results